_(7184104335).webp)
Why Failure-to-Market Claims Are Preempted Under Federal Law
.png)
This short white paper addresses preemption arguments relevant to “failure to market” claims, which cover those cases in which plaintiffs allege that drug companies may be held liable for failing to bring to market, as quickly as possible, drugs that present (allegedly) fewer side effects than other, FDA-approved drugs already on the market.
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The claim rested on factual premises contradicted by all publicly available information, the acceptance of which could seriously disrupt the FDA approval process. This disruption gives rise to an issue the parties did not raise on appeal and that the appeals court never addressed, notwithstanding the complex, comprehensive statutes governing drug approval: these state tort law claims are preempted under theories of both field and conflict (including obstacle) preemption. This White Paper explains why it is imperative for the federal government and private parties to advance these preemption arguments, and why the courts should accept them.
Read the Issue Brief
This white paper was originally published by the Pacific Research Institute's Center for Medical Economics and Innovation.
Economic Dynamism
Defending Technological Dynamism & the Freedom to Innovate in the Age of AI
Human flourishing, economic growth, and geopolitical resilience requires innovation—especially in artificial intelligence.
Partisan Trust in the Federal Reserve
This paper examines partisanship in public perceptions of the Federal Reserve.
Locked Out of the Dream: Regulation Making Homes Unaffordable Around the World
The first in a two-part series on the global housing crisis.
A Most Favored National Policy for Pharma Drugs Makes Sense
"Most favored nation" pricing can help make America's pharmaceutical marketplace more competitive.
.webp)
.webp)
.webp)
Will Companies Doing Business with the Federal Government Face New Litigation Threats?
A new case could establish a precedent to ensnare future military contractors, health care companies, and other federal contractors in hostile state court litigation.
Rise of the AI Oligarchy?
The dominance of a handful of AI companies rhymes with the conditions that allowed "robber barons" to flourish, but the competitive pressures of the AI market will ensure a fluid set of players.
